$AEO

American Eagle Outfitters, Inc (AEO) Q2 2026 Earnings Call Transcript

American Eagle Outfitters (AEO) reported Q2 2026 revenue of $1.4B, up 6% YoY with operating income of $211M. Aerie saw 25% revenue growth and 19% comparable sales growth, while American Eagle had 1% revenue growth and 1% comp decline. New CFO Ravi Thanawala expressed optimism about long-term value creation. AEO reaffirmed its full-year outlook.

Original reporting
Published Sep 10, 2026, 2:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 12:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
American Eagle Outfitters, Inc (AEO) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AEOBullishMed
01

Why it matters

The disclosed numbers exceed prior expectations, especially the tariff refund benefit, suggesting near‑term upside.

02

Market read

First disclosure of Q2 2026 results provides fresh data for traders to adjust positions.

03

What to watch

Aerie's 25% revenue growth could drive future earnings acceleration.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release

Background

American Eagle Outfitters reported its Q2 2026 results via an earnings call transcript.

Company-level read

Ticker impact

$AEOBullishHigh confidence
Context

Q2 2026 earnings call disclosed revenue of $1.4B, comparable sales growth of 6% and a $161M tariff refund benefit.

Expected impact

Potential modest rally ahead of guidance release.

Evidence & confidence

First‑time disclosure of quarterly results with better‑than‑expected comps and a large one‑time benefit.

Market effects

Retail apparel sector may see renewed confidence from AEO's performance.

U.S. consumer discretionary outlook slightly improved.

Limited to U.S. apparel market; no broader macro effect.

Counterpoint

One‑time tariff refund masks underlying margin pressure; watch for guidance.

Key entities

  • American Eagle Outfitters, Inc.

    U.S. apparel retailer (ticker AEO).

Related articles

$AEOMed

BMO raises American Eagle Outfitters stock price target on Aerie momentum

BMO Capital raised its price target on American Eagle Outfitters (NYSE:AEO) to $20 from $18, citing strong Aerie brand momentum and improved women's bottoms sales. The stock trades at $17.41 with a P/E ratio of 8.93. BMO expects upside to Q4 gross margin guidance due to lower tariff rates. AEO reported Q2 earnings of $0.79 per share on $1.38 billion revenue, beating estimates. TD Cowen cut its target to $16, while UBS lowered its target to $27 but maintained a Buy rating.

$AEOHighAI 8/10

Earnings Guidance Lift Could Change The Bull Case For American Eagle Outfitters (AEO)?

American Eagle Outfitters (AEO) reported Q2 2026 sales of $1.38B, net income of $134.08M, and EPS of $0.80. The company issued Q3 and full-year 2026 operating income guidance of $110M-$115M and $540M-$550M, respectively. Analysts highlight execution around inventory, markdowns, and digital productivity as key catalysts, while noting risks from consumer caution and cost pressures. The company declared a quarterly dividend of $0.125 per share.

$AEOMedAI 8/10

American Eagle Goes on Sale: Is It Time to Buy?

American Eagle reported Q2 revenue of $1.4B, up 8%, beating expectations. Aerie and OFFLINE segments drove growth, while the core brand faced challenges. Margins were impacted by tariff refunds and markdowns. Analysts trimmed price targets, but the consensus suggests 35% upside. Institutional investors own 98% of the float, showing bullish signs. The core brand's turnaround is a key risk.

$AAPLMed

Apple, Compass Pathways, Aritzia and more analyst calls of the week

Dell shares rose 11% to a record high after RBC initiated coverage with an Outperform rating and $640 target, citing strong AI and PC demand. Apple shares gained 3.1% after unveiling its first foldable iPhone, the iPhone Duo, priced at $1,999 and above. AstraZeneca's shares remained flat despite mixed analyst views on its drug tozorakimab. Compass Pathways shares climbed 4% on positive Phase III study data for its psilocybin treatment.